Previous Article | Next Article 
Journal of Virology, June 2000, p. 5266-5272, Vol. 74, No. 11
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Expression of Hepatitis B Virus X Protein Does Not
Alter the Accumulation of Spontaneous Mutations in Transgenic
Mice
Charles R.
Madden,1
Milton J.
Finegold,2 and
Betty L.
Slagle1,*
Department of Molecular Virology and
Microbiology,1 and Department of
Pathology,2 Baylor College of Medicine,
Houston, Texas 77030
Received 14 December 1999/Accepted 10 March 2000
 |
ABSTRACT |
Chronic infection with hepatitis B virus (HBV) is one of the major
etiological factors in the development of human hepatocellular carcinoma. Transgenic mice that express the HBV X protein (HBx) have
previously been shown to be more sensitive to the effects of
hepatocarcinogens, although the mechanism for this cofactor role
remains unknown. The ability of HBx to inhibit DNA repair in
transiently transfected cell lines suggests one possible pathway. In
the present study, primary hepatocytes isolated from transgenic mice
that possess the HBV X gene under the control of the human
-1-antitrypsin regulatory region (ATX mice) were found to be deficient in their ability to conduct unscheduled DNA synthesis in
response to UV-induced DNA damage. In order to measure the impact of
HBx expression on DNA repair in vivo, double-transgenic mice that
express HBx and possess a bacteriophage lambda transgene were
sacrificed at 30, 90, and 240 days of age. Mutation frequency was
determined for high-molecular-weight liver DNA of ATX and control mice
by functional analysis of the lambda transgene. Expression of HBx did
not significantly increase the accumulation of spontaneous mutations.
These results are consistent with previous studies of HBx transgenic
mice in which no effect of HBx on liver histology was apparent. This
new animal model provides a powerful system in which to investigate the
in vivo cooperation between HBx expression and environmental carcinogens.
 |
INTRODUCTION |
The hepatitis B virus (HBV) X
protein (HBx) is a 17-kDa regulatory protein necessary for the
establishment of hepadnaviral infection in woodchucks and, presumably,
in all mammals (9, 65). Detectable in both the cytoplasm and
nucleus of infected cells (13, 38, 48, 56), the essential
role(s) for HBx in the life cycle of the virus remains to be
established. Although HBx does not bind DNA directly, it is capable of
transactivating cellular genes (reviewed in references 6, 8,
45, and 51) and can induce protein kinase
signaling cascades (3, 13, 29, 37). In addition to
interacting with numerous cellular proteins (reviewed in reference
16), HBx demonstrates a deoxy-ATPase activity
(12).
Chronic infection with HBV is considered a major risk factor for the
development of human hepatocellular carcinoma (HCC) (1, 49),
but the exact mechanism(s) by which HBV infection leads to the
development of liver cancer remains to be elucidated. An increased rate
of hepatocyte cell death and regeneration caused by the host immune
response to viral antigens undoubtedly contributes to the pathology of
chronic HBV infection (reviewed in references 11 and
49). Several lines of evidence indicate that HBx may also contribute to the development of HCC. Although the majority of HBx
transgenic mouse lines do not demonstrate an increased incidence of
liver cancer under normal conditions (5, 14, 21, 34, 39,
43), such mice are more susceptible to the tumorigenic effects of
hepatocarcinogens (14, 50) or the oncogene c-myc
(54). Based on these observations, HBx is believed to be an
important cofactor in HBV-associated liver cancer.
HBx may influence the development of liver cancer by multiple
mechanisms. Its transactivation of cellular genes (6, 8, 45,
51) as well as the induction of one or more signaling pathways
(3, 13, 26, 29, 35, 37) may lead to the up-regulation of
cellular oncogenes (54, 63) or to changes in cell cycle
progression (4) and/or regulation. Indeed, HBx was shown to
induce cell cycle progression in quiescent skin fibroblasts (31). HBx has also been shown to interact with at least 3 proteins or protein complexes that are directly involved in DNA repair: p53 (17, 57), TFIIH (42), and DDB1 (previously
known as UVDDB1 or XAP1) (33, 48). The latter data suggests
that HBx expression could cause an accumulation of DNA mutations by
indirectly compromising the repair ability of cells. This is
particularly intriguing given the strong correlation between chronic
HBV infection, aflatoxin B1 exposure, and the development of HCC
(18, 53, 62).
Experimental evidence that HBx inhibits DNA repair comes from studies
using transiently transfected immortalized tissue culture cell lines
and primary mouse hepatocytes. These studies concluded that there was
significant inhibition (25 to 60%) of global nucleotide excision
repair (NER) in response to either UV or aflatoxin B1 exposure (2,
20, 25, 41). Although the studies clearly demonstrate that HBx
compromises NER in eukaryotic cells, the actual mechanism by which it
inhibits repair remains unknown. In addition, the impact of
HBx-mediated inhibition of repair in vivo remains to be established.
The purpose of the present study was to extend the cell culture DNA
repair studies into an in vivo setting. The unscheduled DNA synthesis
assay was first used to demonstrate that primary hepatocyte cultures
derived from HBx transgenic mice are deficient in NER relative to
primary hepatocytes derived from a wild-type mouse. In order to measure
the impact of HBx on the accumulation of mutations in vivo, we
generated a double-transgenic mouse line that expresses HBx and
possesses an integrated lambda transgene, allowing measurement of
mutation frequency (MF) (30). Histological examination of
mouse liver tissue did not reveal any consistent liver abnormalities in
these double-transgenic mice. The expression of HBx did not
significantly increase the accumulation of spontaneous mutations in
high-molecular-weight (HMW) liver DNA, nor did it alter the spectrum of
mutations that occurred. Importantly, these studies establish and
characterize a new animal model in which the effects of HBx on MF can
be measured upon exposure to mutagenic agents, a situation that more
closely resembles the synergism between chronic HBV infection and
environmental carcinogens in the etiology of human liver cancer.
 |
MATERIALS AND METHODS |
Transgenic mice.
Transgenic mice harboring the X
gene (nucleotides 1376 to 1840 of subtype adw2) under the
control of the human
-1-antitrypsin inhibitor regulatory region (ATX
mice) (34, 50) were maintained by breeding of hemizygous ATX
males (ICR × B6C3) with wild-type females (ICR). Hemizygous ATX
females (ICR × B6C3) were then mated with homozygous
males
(C57BL/6 Big Blue) (30) obtained from Stratagene
Corporation, and the male F1 progeny were used for this
study. At appropriate time points (30, 90, and 240 days of age), mice
were sacrificed and portions of three liver lobes were fixed in 10%
neutral buffered formalin (16 h) and 70% ethanol. Tissues were
paraffin embedded, and coded hematoxylin-and-eosin-stained sections
submitted for histological analysis by M.J.F. Remaining tissue was
frozen in liquid nitrogen and stored for later experiments.
Southern hybridization.
HMW DNA was purified from transgenic
mouse tail samples by using the Wizard Genomic DNA Purification Kit
(Promega). DNA was digested with BamHI, was resolved on a
1% agarose gel, and was transferred to a nylon membrane (Boehringer
Mannheim). X-gene-specific probe DNA was prepared by PCR
amplification of HBV plasmid DNA by using the primer set
5'-ATGGCTGCTAGGCTGTACTG-3' and
5'-CTACAAGAGATGATTAGGCAGA-3'. Probe DNA for the
cII gene was amplified from 3 µg of homozygous Big Blue
mouse DNA by using the cII-specific primer set
5'-ACCACACCTATGGTGTATGCA-3' and
5'-GTCATAATGACTCCTGTTGATAG-3'. DNA was radiolabeled with
[32P]dCTP (3,000 Ci/mmole) (ICN) by using the Rediprime
II random priming labeling kit (Amersham Pharmacia). Standard
conditions for hybridizations and X-ray film exposures were used
(46). All mice (ATX and wild type) used for this study
possessed approximately 40 copies of the
transgene. ATX mice also
harbored 10 to 15 copies of the ATX transgene.
Immunoprecipitation and Western blot verification of HBx
expression.
Tissue extracts were prepared by homogenizing liver
tissue in Extraction buffer (50 mM Tris-HCl, pH 8.0; 100 mM NaCl; and 1% NP-40). Immunoprecipitation and Western blot analysis were used to
verify expression of HBx, as described previously (50). Briefly, following electrophoresis on sodium dodecyl sulfate-15% polyacrylamide gels, separated proteins were transferred to
nitrocellulose filters. The presence or absence of HBx was verified by
using rabbit anti-HBx polyclonal serum, an avidin-biotin detection kit (Vector Laboratories), and chemiluminescence (Amersham Pharmacia).
Isolation of primary hepatocytes.
Primary mouse hepatocytes
from ATX and wild-type mice were obtained by liver perfusion
(59). In brief, mice were anesthetized and a V incision was
made to expose the internal organs. The flushed liver was perfused with
Earle's balanced salt solution plus collegenase (0.3 mg/ml) and
ovomucoid trypsin inhibitor (0.04 mg/ml). After several minutes of
perfusion, the liver was removed, and loose hepatocytes were dispersed
in Williams Media E (WME) plus 1% fetal calf serum. Following
filtration to remove nonhepatocyte debris, cells were washed and plated
on 60-mm-diameter tissue culture dishes. After 2 h of incubation
at 37°C, the adherent hepatocytes were refed with serum-free WME (WME
plus 30 nM selenium, 10 µg of insulin per ml, 10 µg transferrin,
100 nM somatotropin, 1 µM thyroid hormone T3, 1 µM dexamethasone,
50 ng of epidermal growth factor per ml, and 25 µg of gentamycin per
ml [15]) and were incubated at 37°C overnight.
UDS assay.
The induction of unscheduled DNA synthesis (UDS)
by UV and the subsequent incorporation of [3H]thymidine
into repaired DNA was performed as previously described (2).
Approximately 24 h after attachment, hepatocyte cultures were
washed with buffered saline and were exposed to 0 or 20 J of UV
(254 nm) per m2 in a Stratalinker (Stratagene Biocrest).
Cultures were immediately refed with serum-free WME plus 5 µCi
[3H]thymidine per ml and were incubated for 1 h at
37°C. Cells were harvested by incubation with phosphate-buffered
saline plus trypsin and were rinsed with phosphate-buffered saline. HMW
DNA was isolated from the cell suspensions by using the QIAamp tissue
kit (QIAGEN). The amount of [3H]thymidine incorporation
was measured by standard liquid scintillation counting techniques. DNA
concentration was determined spectrophotometrically and used to
normalize values obtained by liquid scintillation counting. Results
reported for each animal were based on counts per minute per microgram
of DNA calculated from at least three plate replicates (three
UV-exposed and three unexposed plates). To calculate fold induction,
average values for UV-exposed plates were divided by the average value
for unexposed hepatocytes of the same genotype. To facilitate
comparison among different matched sets of hepatocyte cultures, fold
induction values for wild-type cultures were set to 100%, and the
values for ATX cultures were then converted to percentage relative to
wild type in that experiment.
Packaging of lambda phage DNA and plaque assays.
Liver HMW
DNA for use in the Big Blue mutagenesis assay was isolated by using the
RecoverEase system (Stratagene Biocrest) under conditions recommended
by the supplier. Importantly, the RecoverEase system uses no phenol or
chemical extractions that may further damage the DNA. Liver HMW DNA was
subsequently incubated with Transpack (Stratagene Biocrest) to excise
and package the lambda phage genome. Packaged DNA was then incubated
with a suspension (optical density at 600 nm = 0.5) of
Escherichia coli G1250 (G1217hflA::Tn5 hflB29 Tn10). Determination of relative mutation frequency
was accomplished by assaying for inactivating mutations in the
bacteriophage lambda cII gene (24). A portion of
diluted culture (1/100) was then plated and incubated at 37°C for
24 h to determine total (cII
plus
cII+) PFU. The remaining culture was plated and
incubated at 24°C for 48 h, conditions allowing growth of only
mutant plaques. The relative MF was calculated as the ratio of mutant
PFU to total PFU. All mutant plaques were subsequently isolated and
replated under the same conditions to verify the mutant phenotype.
DNA sequencing.
DNA obtained from cored mutant plaques
(heated to 95°C for 5 min) was amplified by a standard PCR procedure
using cII-specific primers (listed above). Amplified
cII DNA was then sequenced by using a Thermosequenase cycle
sequencing kit (Amersham Pharmacia), and the products were resolved by
electrophoresis on 6% polyacrylamide-urea gels.
TUNEL assays.
Sections cut from paraffin-embedded tissues
were analyzed for apoptosis by using a commercially available kit
(Trevigen) and the manufacturer's protocol. Following the terminal
deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling
(TUNEL) reaction, cells were counterstained, and the percentage of
apoptotic cells was determined by counting 10 consecutive fields, each
containing approximately 300 hepatocytes.
Statistical analysis.
Probability calculations for the UDS,
mutation frequency, and apoptosis assays were performed by using a
two-tailed Student's t test (Microsoft Excel software
package). Standard deviation (SD) and mean values were calculated by
using the same software. The MF value of one ATX mouse lay more than
two SDs from the mean and, on that basis, was excluded from the final
reported results.
 |
RESULTS |
Inhibition of UDS in primary ATX mouse hepatocytes.
The
expression of HBx is known to inhibit NER in transiently transfected
cell culture, and we hypothesized that HBx might exert a similar effect
in primary mouse hepatocytes. To demonstrate this, primary hepatocyte
cultures from ATX and wild-type littermates were obtained by
collagenase perfusion, and the ability of these cells to repair
UV-induced DNA damage was then measured in the UDS assay as previously
described (2). Compared to hepatocytes from wild-type mice,
hepatocytes derived from ATX mice demonstrated a significant reduction
in their ability to repair UV damage (Fig. 1) (P < 0.012). The 27 to 40% reduction measured in murine ATX hepatocytes is similar to the
level of inhibition observed in transiently transfected human HepG2
cell cultures (2, 20). The expression of HBx in hepatocyte
cultures obtained from ATX mice was verified by immunoprecipitation and
Western blot analyses (data not shown). These results establish that
the murine NER pathway is inhibited in hepatocytes that constitutively
express HBx and validate the use of ATX mice for further studies on
inhibition of DNA repair.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 1.
Induction of UDS in primary ATX and wild-type mouse
hepatocytes. The incorporation of [3H]thymidine was
measured in cultures harvested 60 min after exposure to 0 or 20 J
of UV per m2. Results shown were obtained from three
separate experiments using sex-matched ATX and wild-type mouse
littermates. Mean and SD values were calculated from three unexposed-
and three exposed-plate replicates for each genotype. To facilitate
comparison among different matched sets of hepatocyte cultures, fold
induction values for wild-type cultures were set to 100%, and the
values for ATX cultures were then converted to a percentage relative to
the wild type.
|
|
Generation of double-transgenic mice.
After demonstrating that
NER was inhibited in ATX hepatocytes cultured in vitro, we wanted to
examine the effect of HBx expression on the accumulation of endogenous
mutations in vivo. To accomplish this goal, hemizygous ATX females were
crossed with homozygous Big Blue males (Stratagene Biocrest)
(30) which contain 80 copies of an intact bacteriophage
transgene. Progeny mice were genotyped by Southern blot hybridization
(Fig. 2). For the purposes of clarity, single-transgenic mice harboring only
are referred to as wild-type mice, while double-transgenic mice harboring both
and ATX
transgenes are referred to as ATX mice. Male mice were subsequently
sacrificed (at 30, 90, and 240 days of age), and portions of their
livers were used for purification of HMW DNA.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 2.
Detection of ATX and transgenes by Southern blot
hybridization. Transgenic male mice used for this study were generated
as described in Materials and Methods. The migration of cII
and X transgenes is indicated at the right.
|
|
Determination of in vivo mutation frequency.
Purified HMW DNA
was packaged into
phage and used to infect E. coli. The
relative MF of each individual liver was then determined as described
in Materials and Methods. Comparison of the relative mutation
frequencies in 30-day-old mice did not reveal any significant differences between ATX and wild-type mice (Table
1), (P > 0.29). Similarly, animals sacrificed at 90 and 240 days did not show any
genotype-specific differences in the accumulation of mutations (all
P values > 0.34). As a positive control, treatment of
a mouse with the liver carcinogen diethylnitrosamine resulted in a
sixfold increase in MF, verifying that this assay reliably detects
changes in mutation accumulation (data not shown). Expression of HBx
was confirmed for all ATX mice in these experiments by using a
combination immunoprecipitation-Western blot procedure (Fig.
3). These results demonstrate that the
expression of HBx in vivo does not influence the frequency of
spontaneous mutations in liver DNA.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 3.
Detection of HBx in transgenic mouse liver tissue. Shown
is a representative result using immunoprecipitation and Western blot
hybridization to detect HBx in 30-day-old (lanes 1 and 2), 90-day-old
(lanes 3 and 4), and 240-day-old (lanes 5 to 8) mice. HBx expression
was clearly demonstrated in all ATX mice (lanes 1, 3, and 5) and absent
in all wild-type mice (lanes 2, 4, and 6). No protein bands were
detected for 240-day-old ATX and wild-type mice (lanes 7 and 8, respectively) when nonspecific rabbit serum was substituted for rabbit
anti-HBx polyclonal serum during the Western blot hybridization
procedure. All mice used in this study were similarly screened for HBx
expression by this method (data not shown). IgG, immunoglobulin G.
|
|
Sequence analysis of cII mutants.
While HBx
expression did not result in a measurable increase in MF, it was
conceivable that it could cause a change in the spectrum of mutations
by inhibiting the repair of only a certain subset of DNA lesions. To
examine this possibility, the cII genes of mutant phage
recovered from a representative ATX mouse were sequenced. All
identified mutations resulted in amino acid changes within the coding
region of cII (data not shown) and were either transition or
transversion events at G/C base pairs (Table
2). This result is consistent with the
mutation spectrum of lambda cII and lacI genes
reported by other studies utilizing lambda-transgenic mice (24,
44). As in those studies, the majority of transition events
(75%) also occurred at CpG islands, a characteristic unique to
eukaryotes (23). Based on this evidence, we conclude that the majority of the mutations recorded in this assay occurred in the
mouse and not in the E. coli strain used to propagate the bacteriophage. These results also confirm that HBx expression does not
cause gross changes in the spectrum of endogenous DNA mutations in
vivo.
Effect of HBx on apoptosis in vivo.
Several recent studies
have demonstrated that HBx can promote the induction of apoptosis under
specific conditions (28, 40, 52, 55). As DNA damage may also
induce apoptosis (61), we considered the possibility that
HBx-mediated inhibition of DNA repair could lead to an increase in
mutation frequency that was not observable due to a simultaneous
induction of apoptosis in ATX mouse hepatocytes. To test this
hypothesis, paraffin sections of 30-day-old ATX and wild-type mice were
analyzed for apoptosis in situ by TUNEL assay. The prevalence of
TUNEL-positive cells (0.25 to 0.33%) was similar to that
previously reported for hepatocytes in adult C57BL/6 mice
(55). Importantly, no significant difference in the
incidence of TUNEL-positive cells was observed between ATX and
wild-type mice (Table 3). These results
demonstrate that, in the absence of exogenous DNA damage, HBx does not
significantly alter the incidence of apoptosis in our ATX mice.
Histological examination of mouse liver tissue.
Liver tissue
preparations for both ATX and wild-type transgenic mice were coded and
submitted for histological examination to assess the impact of HBx
expression on the architecture of the liver. All mice appeared normal
at the time of sacrifice and, with one exception, did not display any
gross histological abnormalities. A single 240-day-old wild-type mouse
displayed diffuse perivenous and sinusoidal accumulation of lymphocytes
consistent with the development of leukemia. Most histological
observations appeared to be random in distribution, with isolated foci
of inflammation being the most frequently cited abnormality (Table
4). Although mild nuclear polymorphism
(anisocytosis) was noted in several animals, it did not increase in
severity with age. These observations indicate that expression of HBx
does not lead to any consistent histopathological changes in the liver
tissues of ATX-
double-transgenic mice.
 |
DISCUSSION |
Evidence linking HBx expression to the development of
HBV-associated liver cancer comes, in part, from studies of transgenic mouse lines. Although the majority of these mouse lines do not show an
increased incidence of liver cancer, they are more susceptible to the
effects of the hepatocarcinogen diethylnitrosamine and activated
oncogenes (14, 50, 54). These observations led us to
hypothesize that HBx may act as a cofactor in HCC development by
inhibiting DNA repair.
The ability of HBx to inhibit the NER pathway has been demonstrated in
vitro. A study from our laboratory showed that human hepatoblastoma
cell cultures (HepG2) transiently transfected with an HBx expression
plasmid conducted an average of 45% less UDS in response to UV
exposure than control cultures (2). Other research
laboratories, using a variety of cell types and both UV and aflatoxin
B1 as mutagenic agents, have since reported similar results (20,
25, 41). The physiological importance of this inhibition,
however, remains to be explored in vivo. The ATX transgenic mouse line,
which constitutively expresses HBx throughout the life span of the
animal (50), provided an ideal model system for such studies.
As the expression of HBx is known to inhibit NER in transiently
transfected cell cultures, we first determined whether it had a similar
effect in transgenic mouse hepatocytes. The ability of primary ATX
hepatocytes to conduct UDS in response to DNA damage was found to be 27 to 40% less than that measured in wild-type cultures. This result
demonstrates that murine hepatocytes which express HBx are deficient in
global NER and that the extent of inhibition is comparable to that seen
in human HepG2 cell cultures. These results indicate that the ATX mouse
model is valid for further studies on the in vivo effects of this
repair-inhibitory property of HBx.
By using a system specifically designed for the measurement of relative
mutation frequency in vivo (Big Blue mouse mutagenesis system), we were
able to measure the effect of HBx expression on mutation accumulation.
Despite the clear expression of HBx in the liver tissue of mice up to
240 days of age, there was no significant difference in MF values
between ATX and wild-type mice. In a previous study, ATX mice treated
with the carcinogenic agent diethylnitrosamine showed a significant
increase in the development of liver foci relative to treated
nontransgenic mice by 240 days of age (50). By analogy, the
mice used for this study were of sufficient age to reveal a similar
effect of HBx on the accumulation of spontaneous mutations. Previous
studies using Big Blue mice have established the criteria (number of
animals analyzed and number of plaques counted) needed to reliably
discern a twofold difference in average MF values (7). Our
experimental design met or exceeded these guidelines. Furthermore, the
MF values we obtained for both ATX and wild-type mice were comparable
to those reported for wild-type mouse liver tissue by other studies (24, 44). Therefore, we conclude that the expression of HBx did not have a significant effect on liver DNA mutation frequency.
The finding that HBx does not alter liver MF in vivo is consistent with
previous studies of HBx transgenic mice (5, 14, 21, 39, 43).
The contribution of HBx expression to oncogenesis in two transgenic
mouse lines that do develop HCC is open to interpretation (27,
64). In one study, all experimental observations were made by
using mice generated from a single transgenic founder (64).
The ability of HBx to increase the incidence of HCC in a second mouse
line, which was prone to the development liver cancer (27),
agrees with the hypothesis that HBx contributes to, but is not solely
responsible for, oncogenesis.
It is difficult to draw conclusions on the possible effect of HBx on
apoptosis. The expression of HBx sensitizes many cell types (primary
mouse hepatocytes, Chang liver, and HepG2) to a variety of proapoptotic
stimuli such as treatment with tumor necrosis factor alpha,
doxirubicin, anti-Fas antibodies, and serum starvation (28, 40,
52) but inhibits apoptosis in other cell types (REV2 and primary
human fibroblasts) (19, 58). More relevant to the present
study, HBx increased the incidence of apoptosis approximately twofold
in 15-day-old transgenic mice (55). Although no increase was
seen in adult transgenic mice in that study, neither could HBx be
detected. Based on all these studies, we considered the possibility
that sustained HBx expression in the ATX mice could lead to an
increased rate of apoptosis among cells incurring sufficient DNA damage
and that this could minimize our ability to detect HBx-related
differences in MF. However, we did not detect any differences in the
rate of apoptosis between ATX and wild-type mouse liver tissues at 30 days of age, a time point when HBx expression is readily detectable.
Furthermore, the percentage of apoptotic cells determined for both ATX
and wild-type mice in the present study correlated with the percentage
reported previously for nontransgenic control mice (55).
These results indicate that HBx did not have a discernable effect on in
vivo liver apoptosis in the double-transgenic mice used for these experiments.
The inability of HBx to influence MF under normal conditions was not an
unexpected result. DNA repair in mammalian cells can be classified into
four different pathways: direct reversal, mismatch, base excision, and
nucleotide-excision-mediated repair. At this time, we have no evidence
regarding the possible impact of HBx expression on DNA repair pathways
other than NER. Presumably, the low level of mutations incurred by
mouse hepatocyte DNA under the conditions used for the present study
was the result of oxidative metabolism and replication. These
spontaneous lesions are readily removed not only by NER, but by other
repair pathways as well (reviewed in references 36,
47, and 60). This redundancy would
effectively minimize the impact of HBx-mediated inhibition of repair
unless either the DNA damage occurred at a much higher rate (by
exposure to mutagenic agents) or the types of lesions induced were
repaired exclusively by NER. Consequently, the inhibition of NER by HBx
may lead to an increase in MF values only after exposure to exogenous
mutagenic agents such as diethylnitrosamine or aflatoxin B1.
Experiments using mice treated with hepatocarcinogens are now in progress.
The concept that HBV-infected individuals are more susceptible to the
damaging effects of mutagenic agents is very intriguing given what is
known about the development of HCC. In certain geographic regions where
HBV infection is endemic, a strong correlation exists between HBV
status, exposure to aflatoxin B1, and incidence of liver cancer
(18, 53, 62). In addition, increased production of reactive
oxygen species and oxidative damage to DNA occurs in transgenic mice
that develop chronic inflammation in response to the overexpression of
the HBV surface protein (22). Eventually, those mice develop
cirrhosis and liver cancer. Although the expression of HBx has yet to
be demonstrated in HBV surface protein mice, they do possess the
X open reading frame and its native promoter region
(10).
As the role of HBx itself in virus replication remains to be clearly
established, we can only speculate as to whether HBx-mediated inhibition of DNA repair is relevant to the virus life cycle. It is
conceivable that inhibition of repair confers a selective advantage to
the virus by allowing a higher rate of genetic variability during
chronic infection. Alternatively, HBx and cellular repair proteins may
be involved in the conversion of partially double-stranded viral DNA
intermediates into transcription-competent, covalently closed circular
DNA. Finally, HBx may interact with a cellular protein, such as DDB1,
to enhance viral replication or gene expression and by doing so,
inadvertently inhibit DNA repair. Along this line, studies showing a
role for DDB1 in transcription indicate yet another property that could
be targeted by HBx (32). The potential for HBx to influence
the regulatory functions of cellular proteins that are also involved in
DNA repair, such as p53 and DDB1, may play an important role in the
life cycle of HBV and is the subject of ongoing research in our laboratory.
In summary, we have generated a novel double-transgenic mouse line in
which the impact of HBx expression on the accumulation of DNA mutations
in vivo can be measured. Although we found that HBx inhibited NER in
mouse hepatocytes cultured in vitro following exposure to UV, it did
not have any discernible impact on mutation frequency in vivo in the
absence of DNA damage. This evidence, in conjunction with previous
studies, implies that exposure to DNA-damaging agents may be necessary
before HBx significantly affects mutation frequency. With this animal
model, it will now be possible to address such questions in a setting
that more closely resembles the development of HCC in humans.
 |
ACKNOWLEDGMENTS |
This work was supported by NIH research grant CA54557. C.R.M. was
supported by research training grant T32DK07664.
We thank Christopher Wagner, Kristopher Frese, Stephanie Moses, and
Melissa Wentz for technical assistance.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular Virology and Microbiology, Mailstop BCM-385, One Baylor
Plaza, Baylor College of Medicine, Houston, TX 77030-3411. Phone: (713) 798-3006. Fax: (713) 798-5075. E-mail:
bslagle{at}bcm.tmc.edu.
 |
REFERENCES |
| 1.
|
Beasley, R. P.
1988.
Hepatitis B virus. The major etiology of hepatocellular carcinoma.
Cancer
61:1942-1956[CrossRef][Medline].
|
| 2.
|
Becker, S. A.,
T. H. Lee,
J. S. Butel, and B. L. Slagle.
1998.
Hepatitis B virus X protein interferes with cellular DNA repair.
J. Virol.
72:266-272[Abstract/Free Full Text].
|
| 3.
|
Benn, J., and R. J. Schneider.
1994.
Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade.
Proc. Natl. Acad. Sci. USA
91:10350-10354[Abstract/Free Full Text].
|
| 4.
|
Benn, J., and R. J. Schneider.
1995.
Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls.
Proc. Natl. Acad. Sci. USA
92:11215-11219[Abstract/Free Full Text].
|
| 5.
|
Billet, O.,
G. Grimber,
M. Levrero,
K. A. Seye,
P. Briand, and V. Joulin.
1995.
In vivo activity of the hepatitis B virus core promoter:tissue specificity and temporal regulation.
J. Virol.
69:5912-5916[Abstract].
|
| 6.
|
Buendia, M. A.
1992.
Hepatitis B viruses and hepatocellular carcinoma.
Adv. Cancer Res.
59:167-226[Medline].
|
| 7.
|
Callahan, J. D., and J. M. Short.
1995.
Transgenic /lac 1 mutagenicity assay: statistical determination of sample size.
Mutat. Res.
327:201-208[CrossRef][Medline].
|
| 8.
|
Caselmann, W. H.
1996.
Trans-activation of cellular genes by hepatitis B virus proteins: a possible mechanism of hepatocarcinogenesis.
Adv. Virus Res.
47:253-302[Medline].
|
| 9.
|
Chen, H.-S.,
S. Kaneko,
R. Girones,
R. W. Anderson,
W. E. Hornbuckle,
B. C. Tennant,
P. J. Cote,
J. L. Gerin,
R. H. Purcell, and R. H. Miller.
1993.
The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks.
J. Virol.
67:1218-1226[Abstract/Free Full Text].
|
| 10.
|
Chisari, F. V.,
K. Klopchin,
T. Moriyama,
C. Pasquinelli,
H. A. Dunsford,
S. Sell,
C. A. Pinkert,
R. L. Brinster, and R. D. Palmiter.
1989.
Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice.
Cell
59:1145-1156[CrossRef][Medline].
|
| 11.
|
Christen, S.,
T. M. Hagen,
M. K. Shigenaga, and B. N. Ames.
1999.
Chronic inflammation, mutation, and cancer, p. 35-88.
In
J. Parsonet (ed.), Microbes and malignancy: infection as a cause of human cancers. Oxford University Press, New York, N.Y.
|
| 12.
|
De-Medina, T.,
I. Haviv,
S. Noiman, and Y. Shaul.
1994.
The X protein of hepatitis B virus has a ribo-deoxy ATPase activity.
Virology
202:401-407[CrossRef][Medline].
|
| 13.
|
Doria, M.,
N. Klein,
R. Lucito, and R. J. Schneider.
1995.
The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors.
EMBO J.
19:4747-4757.
|
| 14.
|
Dragani, T. A.,
G. Manenti,
H. Farza,
G. Della Porta,
P. Tiollais, and C. Pourcel.
1989.
Transgenic mice containing hepatitis B virus sequences are more susceptible to carcinogen-induced hepatocarcinogenesis.
Carcinogenesis
11:953-956[Abstract/Free Full Text].
|
| 15.
|
Enat, R.,
D. M. Jefferson,
N. Ruiz-Opazo,
Z. Gatmaitan,
L. A. Leinwand, and L. M. Reid.
1984.
Hepatocyte proliferation in vitro: its dependence on the use of serum-free hormonally defined medium and substrata of extracellular matrix.
Proc. Natl. Acad. Sci. USA
81:1411-1415[Abstract/Free Full Text].
|
| 16.
|
Feitelson, M. A., and L. X. Duan.
1997.
Hepatitis B virus x antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma.
Am. J. Pathol.
150:1141-1157[Abstract].
|
| 17.
|
Feitelson, M. A.,
M. Zhu,
L. X. Duan, and W. T. London.
1993.
Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma.
Oncogene
8:1109-1117[Medline].
|
| 18.
|
Ghebranious, N., and S. Sell.
1998.
Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice.
Hepatology
27:383-391[CrossRef][Medline].
|
| 19.
|
Gottlob, K.,
M. Fulco,
M. Levrero, and A. Graessmann.
1998.
The hepatitis B virus HBx protein inhibits caspase 3 activity.
J. Biol. Chem.
273:33347-33353[Abstract/Free Full Text].
|
| 20.
|
Groisman, I. J.,
R. Koshy,
F. Henkler,
J. D. Groopman, and M. A. Alaoui-Jamali.
1999.
Downregulation of DNA excision repair by the hepatitis B virus-x protein occurs in p53-proficient and p53-deficient cells.
Carcinogenesis
20:479-483[Abstract/Free Full Text].
|
| 21.
|
Guidotti, L. G.,
B. Matzke,
H. Schaller, and F. V. Chisari.
1995.
High-level hepatitis B virus replication in transgenic mice.
J. Virol.
69:6158-6169[Abstract].
|
| 22.
|
Hagen, T. M.,
S. Huang,
J. Curnutte,
P. Fowler,
V. Martinez,
C. M. Wehr,
B. N. Ames, and F. V. Chisari.
1994.
Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma.
Proc. Natl. Acad. Sci. USA
91:12808-12812[Abstract/Free Full Text].
|
| 23.
|
Hill, K. A.,
V. L. Buettner,
B. W. Glickman, and S. S. Sommer.
1999.
Spontaneous mutations in the Big Blue transgenic system are primarily mouse derived.
Mutat. Res.
436:11-19[CrossRef][Medline].
|
| 24.
|
Jakubczak, J. L.,
G. Merlino,
J. E. French,
W. J. Muller,
B. Paul,
S. Adhya, and S. Garges.
1996.
Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage lambda transgene target.
Proc. Natl. Acad. Sci. USA
93:9073-9078[Abstract/Free Full Text].
|
| 25.
|
Jia, L.,
X. W. Wang, and C. C. Harris.
1999.
Hepatitis B virus X protein inhibits nucleotide excision repair.
Int. J. Cancer
80:875-879[CrossRef][Medline].
|
| 26.
|
Kekule, A. S.,
U. Lauer,
L. Weiss,
B. Luber, and P. H. Hofschneider.
1993.
Hepatitis B virus transactivator HBx uses a tumour promoter signaling pathway.
Nature
361:742-745[CrossRef][Medline].
|
| 27.
|
Kim, C.-M.,
K. Koike,
I. Saito,
T. Miyamura, and G. Jay.
1991.
HBx gene of hepatitis B virus induces liver cancer in transgenic mice.
Nature
351:317-320[CrossRef][Medline].
|
| 28.
|
Kim, H.,
H. Lee, and Y. Yun.
1998.
X-gene product of hepatitis B virus induces apoptosis in liver cells.
J. Biol. Chem.
273:381-385[Abstract/Free Full Text].
|
| 29.
|
Klein, N. P., and R. J. Schneider.
1997.
Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras.
Mol. Cell. Biol.
17:6427-6436[Abstract].
|
| 30.
|
Kohler, S. W.,
G. S. Provost,
P. L. Kretz,
A. Fieck, and J. M. Short.
1990.
An in vivo assay using transgenic mice to analyze spontaneous and induced mutations at the nucleic acid level.
Strategies
3:19-21.
|
| 31.
|
Koikie, K.,
K. Moriya,
H. Yotsuyanagi,
S. Iino, and K. Kurokawa.
1994.
Induction of cell cycle progression by hepatitis B virus HBx gene expression in quiescent mouse fibroblasts.
J. Clin. Investig.
94:44-49.
|
| 32.
|
Krishnamoorthy, R. R.,
T.-H. Lee,
J. S. Butel, and H. K. Das.
1997.
Apolipoprotein B gene regulatory factor-2 (BRF-2) is structurally and immunologically highly related to hepatitis B virus associated protein-1 (XAP-1).
Biochemistry
36:960-969[CrossRef][Medline].
|
| 33.
|
Lee, T.-H.,
S. J. Elledge, and J. S. Butel.
1995.
Hepatitis B virus X protein interacts with a probable cellular DNA repair protein.
J. Virol.
69:1107-1114[Abstract].
|
| 34.
|
Lee, T.-H.,
M. F. Finegold,
R.-F. Shen,
J. L. DeMayo,
S. L. C. Woo, and J. S. Butel.
1990.
Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice.
J. Virol.
64:5939-5947[Abstract/Free Full Text].
|
| 35.
|
Lee, Y. H., and Y. Yun.
1998.
HBx protein of hepatitis B virus activates Jak1-STAT signaling.
J. Biol. Chem.
273:25510-25515[Abstract/Free Full Text].
|
| 36.
|
Marra, G., and P. Schar.
1999.
Recognition of DNA alterations by the mismatch repair system.
Biochem. J.
338:1-13.
|
| 37.
|
Natoli, G.,
M. L. Avantaggiati,
P. Chirillo,
P. L. Puri,
A. Ianni,
C. Balsano, and M. Levrero.
1994.
Ras- and Raf-dependent activation of c-Jun transcriptional activity by the hepatitis B virus transactivator pX.
Oncogene
9:2837-2843[Medline].
|
| 38.
|
Nomura, T.,
Y. Lin,
D. Dorjsuren,
S. Ohno,
T. Yamashita, and S. Murakami.
1999.
Human hepatitis B virus X protein is detectable in nuclei of transfected cells, and is active for transactivation.
Biochim. Biophys. Acta
1453:330-340[Medline].
|
| 39.
|
Perfumo, S.,
L. Amicone,
S. Colloca,
M. Giorgo,
L. Pozzi, and M. Tripodi.
1992.
Recognized efficiency of the hepatitis B virus polyadenylation signal is tissue specific in transgenic mice.
J. Virol.
66:6819-6823[Abstract/Free Full Text].
|
| 40.
|
Pollicino, T.,
O. Terradillos,
H. Lecoeur,
M. L. Gougeon, and M. A. Buendia.
1998.
Pro-apoptotic effect of the hepatitis B virus X gene.
Biomed. Pharmacother.
52:363-368[CrossRef][Medline].
|
| 41.
|
Prost, S.,
J. M. Ford,
C. Taylor,
J. Doig, and D. J. Harrison.
1998.
Hepatitis B x protein inhibits p53-dependent DNA repair in primary mouse hepatocytes.
J. Biol. Chem.
273:33327-33332[Abstract/Free Full Text].
|
| 42.
|
Qadri, I.,
J. W. Conaway,
R. C. Conaway,
J. Schaack, and A. Siddiqui.
1996.
Hepatitis B virus transactivator protein, HBx, associates with the components of TFIIH and stimulates the DNA helicase activity of TFIIH.
Proc. Natl. Acad. Sci. USA
93:10578-10583[Abstract/Free Full Text].
|
| 43.
|
Reifenberg, K.,
J. Lohler,
H.-P. Pudollek,
E. Schmitteckert,
G. Spindler,
J. Kock, and H.-J. Schlickt.
1999.
Long-term expression of the hepatitis B virus core-e- and X-proteins does not cause pathologic changes in transgenic mice.
J. Hepatol.
26:119-130.
|
| 44.
|
Ross, J. A., and S. A. Leavitt.
1998.
Induction of mutations by 2-acetylaminofluorene in lac1 transgenic B6C3F1 mouse liver.
Mutagenesis
13:173-179[Abstract/Free Full Text].
|
| 45.
|
Rossner, M. T.
1992.
Hepatitis B virus X-gene product: a promiscuous transcriptional activator.
J. Med. Virol.
36:101-117[CrossRef][Medline].
|
| 46.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
|
| 47.
|
Sancar, A.
1996.
DNA excision repair.
Annu. Rev. Biochem.
65:43-81[CrossRef][Medline]. (Erratum, 66:VII, 1997.)
|
| 48.
|
Sitterlin, D.,
T.-H. Lee,
S. Prigent,
P. Tiollais,
J. S. Butel, and C. Transy.
1997.
Interaction of the UV-damaged DNA-binding protein with hepatitis B virus X protein is conserved among mammalian hepadnaviruses and restricted to transactivation-proficient X-insertion mutants.
J. Virol.
71:6194-6199[Abstract].
|
| 49.
|
Slagle, B. L.,
S. A. Becker, and J. S. Butel.
1994.
Hepatitis viruses and liver cancer, p. 149-171.
In
A. Minson, J. Neil, and M. McCrae (ed.), Viruses and cancer, vol. 51. University of Cambridge, Cambridge, England.
|
| 50.
|
Slagle, B. L.,
T.-H. Lee,
D. Medina,
M. J. Finegold, and J. S. Butel.
1996.
Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene.
Mol. Carcinog.
15:261-269[CrossRef][Medline].
|
| 51.
|
Slagle, B. L.,
T.-H. Lee, and J. S. Butel.
1992.
Hepatitis B virus and hepatocellular carcinoma.
Prog. Med. Virol.
39:167-203[Medline].
|
| 52.
|
Su, F., and R. J. Schneider.
1997.
Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor .
Proc. Natl. Acad. Sci. USA
94:8744-8749[Abstract/Free Full Text].
|
| 53.
|
Sun, Z.,
P. Lu,
M. H. Gail,
D. Pee,
Q. Zhang,
L. Ming,
J. Wang,
Y. Wu,
G. Liu, and Y. Zhu.
1999.
Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1.
Hepatology
30:379-383[CrossRef][Medline].
|
| 54.
|
Terradillos, O.,
O. Billet,
C. A. Renard,
R. Levy,
T. Molina,
P. Briand, and M. A. Buendia.
1997.
The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice.
Oncogene
14:395-404[CrossRef][Medline].
|
| 55.
|
Terradillos, O.,
T. Pollicino,
H. Lecoeur,
M. Tripodi,
M. L. Gougeon,
P. Tiollais, and M. A. Buendia.
1998.
p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro.
Oncogene
17:2115-2123[CrossRef][Medline].
|
| 56.
|
Wang, W. L.,
W. T. London,
L. Lega, and M. A. Feitelson.
1991.
HBxAg in the liver from carrier patients with chronic hepatitis and cirrhosis.
Hepatology
14:29-37[Medline].
|
| 57.
|
Wang, X. W.,
K. Forrester,
H. Yeh,
M. A. Feitelson,
J. R. Gu, and C. C. Harris.
1994.
Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3.
Proc. Natl. Acad. Sci. USA
91:2230-2234[Abstract/Free Full Text].
|
| 58.
|
Wang, X. W.,
M. K. Gibson,
W. Vermeulen,
H. Yeh,
K. Forrester,
H.-W. Sturzbecher,
J. H. J. Hoeijmakers, and C. C. Harris.
1995.
Abrogation of p53-induced apoptosis by the hepatitis B virus X gene.
Cancer Res.
55:6012-6016[Abstract/Free Full Text].
|
| 59.
|
Williams, G. M.,
M. F. Laspia, and V. C. Dunkel.
1982.
Reliability of the hepatocyte primary culture/DNA repair test in testing of coded carcinogens and non-carcinogens.
Mutat. Res.
97:359-370[Medline].
|
| 60.
|
Wood, R. D.
1996.
DNA repair in eukaryotes.
Annu. Rev. Biochem.
67:135-167[CrossRef][Medline].
|
| 61.
|
Wyllie, A. H.,
C. O. Bellamy,
V. J. Bubb,
A. R. Clarke,
S. Corbet,
L. Curtis,
D. J. Harrison,
M. L. Hooper,
N. Toft,
S. Webb, and C. C. Bird.
1999.
Apoptosis and carcinogenesis.
Br. J. Cancer
80(Suppl. 1):34-37.
|
| 62.
|
Yeh, F.-S.,
M. C. Yu,
C.-C. Mo,
S. Luo,
M. J. Tong, and B. E. Henderson.
1989.
Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China.
Cancer Res.
49:2506-2509[Abstract/Free Full Text].
|
| 63.
|
Yoo, Y. D.,
H. Ueda,
K. Park,
K. C. Flanders,
Y. I. Lee,
G. Jay, and S. J. Kim.
1996.
Regulation of transforming growth factor- 1 expression by the hepatitis B virus (HBV) X transactivator.
J. Clin. Investig.
97:388-395[Medline].
|
| 64.
|
Yu, D. Y.,
H. B. Moon,
J. K. Son,
S. Jeong,
S. L. Yu,
H. Yoon,
Y. M. Han,
C. S. Lee,
J. S. Park,
C. H. Lee,
B. H. Hyun,
S. Murakami, and K. K. Lee.
1999.
Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein.
J. Hepatol.
31:123-132[CrossRef][Medline].
|
| 65.
|
Zoulim, F.,
J. Saputelli, and C. Seeger.
1994.
Woodchuck hepatitis virus X protein is required for viral infection in vivo.
J. Virol.
68:2026-2030[Abstract/Free Full Text].
|
Journal of Virology, June 2000, p. 5266-5272, Vol. 74, No. 11
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lee, A. T. C., Ren, J., Wong, E.-T., Ban, K. H. K., Lee, L. A., Lee, C. G. L.
(2005). The Hepatitis B Virus X Protein Sensitizes HepG2 Cells to UV Light-induced DNA Damage. J. Biol. Chem.
280: 33525-33535
[Abstract]
[Full Text]
-
Bouchard, M. J., Schneider, R. J.
(2004). The Enigmatic X Gene of Hepatitis B Virus. J. Virol.
78: 12725-12734
[Full Text]
-
Madden, C. R., Finegold, M. J., Slagle, B. L.
(2002). Altered DNA Mutation Spectrum in Aflatoxin B1-Treated Transgenic Mice That Express the Hepatitis B Virus X Protein. J. Virol.
76: 11770-11774
[Abstract]
[Full Text]
-
Nag, A., Datta, A., Yoo, K., Bhattacharyya, D., Chakrabortty, A., Wang, X., Slagle, B. L., Costa, R. H., Raychaudhuri, P.
(2001). DDB2 Induces Nuclear Accumulation of the Hepatitis B Virus X Protein Independently of Binding to DDB1. J. Virol.
75: 10383-10392
[Abstract]
[Full Text]
-
Madden, C. R., Finegold, M. J., Slagle, B. L.
(2001). Hepatitis B Virus X Protein Acts as a Tumor Promoter in Development of Diethylnitrosamine-Induced Preneoplastic Lesions. J. Virol.
75: 3851-3858
[Abstract]
[Full Text]
-
Jaitovich-Groisman, I., Benlimame, N., Slagle, B. L., Perez, M. H., Alpert, L., Song, D. J., Fotouhi-Ardakani, N., Galipeau, J., Alaoui-Jamali, M. A.
(2001). Transcriptional Regulation of the TFIIH Transcription Repair Components XPB and XPD by the Hepatitis B Virus x Protein in Liver Cells and Transgenic Liver Tissue. J. Biol. Chem.
276: 14124-14132
[Abstract]
[Full Text]